New drug shows promise for severe nasal polyp patients who don't respond to steroids

A new study evaluates mepolizumab, a biologic medication, as a treatment option for patients with severe chronic rhinosinusitis and nasal polyps who haven't benefited from standard steroid therapy. The finding could expand treatment options for a condition that affects millions globally and drives significant healthcare costs and patient disability.

Originaltitel: Evaluating treatment response to mepolizumab in patients with severe CRSwNP